Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Opt-out policy at a syringe service program increased HIV/HCV testing
Key clinical point: Opt-out testing at a syringe service program (SSP) increased HIV/HCV testing.
Major finding: There was a significant increase in uptake of HIV/HCV testing by 42.4% after changing to opt-out testing.
Study details: The study assessed 512 SSP participants 15 months prior to and 547 SSP participants 22 months after implementation of bundled HIV/HCV opt-out testing.
Disclosures: The authors reported funding from the National Cancer Institute and the Frontlines of Communities in the United States, a program of Gilead Sciences. They provided no other disclosures.
Citation:
Bartholomew TS et al. Int J Drug Policy. 2020. doi: 10.1016/j.drugpo.2020.102875.